Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-08-10 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "半年度报告 2025" which translates to "Half-Year Report 2025". It contains detailed financial data such as revenue, profit, assets, liabilities, and operational analysis for the period January 1, 2025 to June 30, 2025. The content includes comprehensive financial statements, business overview, risk disclosures, and management discussion of financial results. The length is substantial (15,000 characters) and it is not merely an announcement or a certification. The document is clearly a comprehensive interim financial report covering a period shorter than a full fiscal year, consistent with the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-10 Chinese
关于调整2025年股票期权激励计划行权价格及数量的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding adjustments to the exercise price and quantity of its 2025 stock option incentive plan. It details the approval process, adjustment methods, and the impact on the company. The content focuses on changes to stock option plans, which relate to capital structure and equity incentives. There is no indication that this is a full financial report, earnings release, or management discussion. It is not a proxy solicitation or voting result announcement. The document is a formal announcement about changes in the company's stock option incentive plan, which falls under capital or financing updates. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the adjustment, not merely a brief notice or report publication announcement.
2025-08-10 Chinese
关于召开2025年第三次临时股东会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the company's 2025 third extraordinary general meeting of shareholders, including details about the meeting date, voting methods (onsite and online), eligibility, agenda items, registration procedures, and proxy authorization. It does not contain financial statements or results but is an announcement related to a shareholder meeting. The document length is 2681 characters, which is relatively short and consistent with a meeting notice rather than a full report. There is no indication that this is a report itself or a voting result announcement. Therefore, the document fits the category of a Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to prepare for voting at the meeting.
2025-08-10 Chinese
募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management, storage, and actual use of funds raised through a public stock issuance by Shanxi Jinbo Biopharmaceutical Co., Ltd. It includes specifics on the total amount raised, net proceeds, timing of fund receipt, storage accounts, management policies, actual usage, changes in fund usage, and compliance with regulatory requirements. It also references audit reports verifying the capital raised and fund usage. The document is not a general annual or quarterly report, nor is it a simple announcement or certification. It specifically focuses on the use and management of capital raised, which aligns with the definition of a Capital/Financing Update (CAP). The length and detail confirm it is a substantive report, not just an announcement or certification. Therefore, the appropriate classification is CAP.
2025-08-10 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 98% confidence The document is titled “2025年半年度报告摘要” (2025 Half‐Year Report Summary) for Shanxi Jinbo Bio‐Pharmaceutical Co., Ltd. It contains substantive semi‐annual financial data and analysis (assets, revenues, net profit, cash flows, EPS, shareholding tables, asset pledges, etc.). It is not merely an announcement of report availability but includes actual financial statements and key metrics for the interim period. Therefore, it should be classified as an Interim / Quarterly Report. H1 2025
2025-08-10 Chinese
第四届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 13th meeting of the 4th Board of Directors of Shanxi Jinbo Biopharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to other reports and announcements such as the 2025 semi-annual report, dividend distribution plan, and stock option adjustments. The document is not the report itself but a formal board meeting resolution announcement. It does not contain actual financial statements or detailed financial data but rather decisions and approvals made by the board. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 3057 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report.
2025-08-10 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.